(Q35053948)

6 August 2017

1 reference

title

The biology of breast carcinoma. (English)

1 reference

6 August 2017

Judith Clancy Keen

1

0 references

author name string

Nancy E Davidson

series ordinal

2

1 reference

PubMed ID

12548582

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

6 August 2017

1 reference

6 August 2017

97

1 reference

6 August 2017

825-833

1 reference

6 August 2017

3 Suppl

1 reference

Li-Fraumeni syndrome--a molecular and clinical review

6 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

21 January 2018

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Breast cancer: hormones and other risk factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Suppression by estrogen receptor beta of AP-1 mediated transactivation through estrogen receptor alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Cyclins and breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Acetylation and chromosomal functions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Molecular biology. Methylation talk between histones and DNA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Methylation-induced repression--belts, braces, and chromatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Cloning of a novel receptor expressed in rat prostate and ovary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

ER beta: identification and characterization of a novel human estrogen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Estrogen receptors and proliferation markers in primary and recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Progesterone receptor A and B isoforms in the human breast and its disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Differential expression of nuclear retinoid receptors in normal and malignant prostates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Loss of heterozygosity in normal tissue adjacent to breast carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

A synthetic oestrogen antagonist, tamoxifen, inhibits oestrogen-induced transcriptional, but not post-transcriptional, regulation of gene expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Identification of p53 as a sequence-specific DNA-binding protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Concomitant inactivation of p53 and Chk2 in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Suppression of human colorectal carcinoma cell growth by wild-type p53

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Oncogenic forms of p53 inhibit p53-regulated gene expression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Contribution of estrogen receptor alpha to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression*.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Chromosome instability in fibroblasts derived from Li-Fraumeni syndrome families without TP53 mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

The relationship between radiation-induced G(1)arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

BRCA1 and BRCA2 and the genetics of breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

BRCA1 and BRCA2 in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Hereditary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11126

7 January 2021

Identifiers

DOI

10.1002/CNCR.11126

1 reference

6 August 2017

1 reference

PubMed ID

12548582